Canada - English - Health Canada

greer laboratories inc - dermatophagoides pteronyssinus - liquid - 30000unit - dermatophagoides pteronyssinus 30000unit - allergenic extracts

United States - English - NLM (National Library of Medicine)

greer laboratories, inc. - dermatophagoides farinae (unii: pr9u2ypf3q) (dermatophagoides farinae - unii:pr9u2ypf3q) - dermatophagoides farinae 5000 [au] in 1 ml - greer standardized mite ( dermatophagoides farinae and/or dermatophagoides pteronyssinus ) extracts are allergenic extracts indicated for: - skin test diagnosis of mite allergy - treatment of patients with mite-induced allergic asthma, rhinitis and conjunctivitis. for immunotherapy, patients must show hypersensitivity to dermatophagoides farinae ( d. farinae ) or dermatophagoides pteronyssinus ( d. pteronyssinus ) based on their clinical history, allergen exposure history, and skin test reactivity. none. 8.1 pregnancy pregnancy category c: animal reproduction studies have not been conducted with greer standardized mite extracts. it is also not known whether greer standardized mite extracts can cause fetal harm when administered to a pregnant woman or whether they can affect reproduction capacity. standardized mite extracts should be given to a pregnant woman only if clearly needed. studies have not been performed in animals to determine whether extracts affect fertility in males or females,

New Zealand - English - Medsafe (Medicines Safety Authority)

ebos group ltd - allergen extracts 0.1 ic/ml (alternaria alternata (50%), alternaria longipes (50%) extracts); allergen extracts 1 ic/ml (alternaria alternata (50%), alternaria longipes (50%) extracts); allergen extracts 10 ic/ml (alternaria alternata (50%), alternaria longipes (50%) extracts) - solution for injection - active: allergen extracts 0.1 ic/ml (alternaria alternata (50%), alternaria longipes (50%) extracts) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water active: allergen extracts 1 ic/ml (alternaria alternata (50%), alternaria longipes (50%) extracts) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water active: allergen extracts 10 ic/ml (alternaria alternata (50%), alternaria longipes (50%) extracts) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water

New Zealand - English - Medsafe (Medicines Safety Authority)

ebos group ltd - allergen extracts 0.1 ic/ml (a. absinthium (25%), t. vulgarae (25%), x. strumarium (25%), c. leucanthemum (25%) pollen extract); allergen extracts 1 ic/ml (a. absinthium (25%), t. vulgarae (25%), x. strumarium (25%), c. leucanthemum (25%) pollen extract); allergen extracts 10 ic/ml (a. absinthium (25%), t. vulgarae (25%), x. strumarium (25%), c. leucanthemum (25%) pollen extract) - solution for injection - active: allergen extracts 0.1 ic/ml (a. absinthium (25%), t. vulgarae (25%), x. strumarium (25%), c. leucanthemum (25%) pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water active: allergen extracts 1 ic/ml (a. absinthium (25%), t. vulgarae (25%), x. strumarium (25%), c. leucanthemum (25%) pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water active: allergen extracts 10 ic/ml (a. absinthium (25%), t. vulgarae (25%), x. strumarium (25%), c. leucanthemum (25%) pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water

United States - English - NLM (National Library of Medicine)

nelco laboratories, inc. - dermatophagoides farinae (unii: pr9u2ypf3q) (dermatophagoides farinae - unii:pr9u2ypf3q) - dermatophagoides farinae 10000 [au] in 1 ml - standardized mite allergenic extracts are intended for use in the diagnosis and therapy of d.farinae and d.pteronyssinus mite allergy, as established by allergy history and skin test reactivity (6,10) . standardized mite extracts are not interchangeable with non standardized mite extracts. to select patients for a confirmation of allergic disease diagnosis and/or treatment with allergen extracts, screening tests should be done using in vivo identification testing methods (i.e. scratch or intradermal testing).(13) standardized mite extract containing equal parts of d.farinae and d.pteronyssinus is intended for therapy only. the use of standardized mites extract is indicated for hypersensitization treatment and may be used as part of the over-all management of the allergic patient. this treatment is particularly to be recommended when a patient's sensitivity to mite has been determined initially by scratch or intradermal skin tests. this product should not be used if the patient has asthma, cardiovascular disea

United States - English - NLM (National Library of Medicine)

antigen laboratories, inc. - dermatophagoides pteronyssinus (unii: 57l1z5378k) (dermatophagoides pteronyssinus - unii:57l1z5378k) - dermatophagoides pteronyssinus 10000 [au] in 1 ml - indications and usage     standardized mite allergenic extract is indicated for diagnostic testing and for the treatment (immunotherapy) of patients whose histories indicate that upon natural exposure to the allergen, they experience allergic symptoms. confirmation is determined by skin testing. an orderly approach to the diagnostic use of allergenic extracts usually begins with direct skin testing. this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing.     mite mixtures should not be used for diagnostic skin testing. the individual mites should be used. mite mixtures may be used for immunotherapy to treat patients who demonstrated sensi­tivity to both d. farinae and d. pteronyssinus mites. patients who react to both d. farinae and d. pteronyssinus have demonstrated a significant cross-reactivity. caution should be used in esca­lating treatment with mite mixtures.21 prick-puncture testing:

United States - English - NLM (National Library of Medicine)

alk-abello a s - dermatophagoides pteronyssinus (unii: 57l1z5378k) (dermatophagoides pteronyssinus - unii:57l1z5378k), dermatophagoides farinae (unii: pr9u2ypf3q) (dermatophagoides farinae - unii:pr9u2ypf3q) - dermatophagoides pteronyssinus 6 [arb'u] - odactra™ is an allergen extract indicated as immunotherapy for the treatment of house dust mite (hdm)-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive in vitro testing for ige antibodies to dermatophagoides   farinae or dermatophagoides   pteronyssinus house dust mites, or by positive skin testing to licensed house dust mite allergen extracts. odactra is approved for use in persons 12 through 65 years of age.  odactra is not indicated for the immediate relief of allergic symptoms. odactra is contraindicated in patients with: - severe, unstable or uncontrolled asthma - a history of any severe systemic allergic reaction - a history of any severe local reaction after taking any sublingual allergen immunotherapy - a history of eosinophilic esophagitis - hypersensitivity to any of the inactive ingredients contained in this product [see description ( 11 )] risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. available data on odactra administered to pregnant women are insufficient to inform associated risks in pregnancy. in an embryo/fetal developmental toxicity study performed in mice, administration of odactra during gestation did not reveal adverse developmental outcomes in fetuses (see 8.1 data ). data animal data in a developmental toxicity study, the effect of odactra on embryo/fetal development was evaluated in mice. animals were administered odactra subcutaneously daily from day 6 to day 17 of the gestation period at doses up to 5 times the human sublingual dose. there were no odactra-related post-implantation losses, fetal malformations or variations. risk summary it is not known whether odactra is excreted in human milk. data are not available to assess the effects of odactra on the breastfed child or on milk production and excretion in the nursing woman. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for odactra and any potential adverse effects on the breastfed child from odactra or from the underlying maternal condition. the safety and effectiveness of odactra have been established in adolescents 12 through 17 years of age. the safety and effectiveness have not been established in persons below 12 years of age. safety and effectiveness have not been established in persons older than 65 years of age.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

stallergènes s.a. - dermatophagoides farinae, allergens 50 ir (tablet 100 ir); dermatophagoides pteronyssinus, allergens 50 ir (tablet 100 ir); dermatophagoides farinae, allergens 150 ir (tablet 300 ir); dermatophagoides pteronyssinus, allergens 150 ir (tablet 300 ir) - sublingual tablet - 100 ir - 300 ir - dermatophagoides farinae, allergens 50 ir; dermatophagoides pteronyssinus, allergens 50 ir; dermatophagoides farinae, allergens 150 ir; dermatophagoides pteronyssinus, allergens 150 ir - house dust mites

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

stallergènes s.a. - dermatophagoides farinae, extract 50 ir; dermatophagoides pteronyssinus, extract 50 ir - sublingual tablet - 100 ir - dermatophagoides farinae, allergens 50 ir; dermatophagoides pteronyssinus, allergens 50 ir - house dust mites

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

stallergènes s.a. - dermatophagoides pteronyssinus, extract 150 ir; dermatophagoides farinae, extract 150 ir - sublingual tablet - 300 ir - dermatophagoides farinae, allergens 150 ir; dermatophagoides pteronyssinus, allergens 150 ir - house dust mites